深圳市18～24月龄婴幼儿孤独症谱系障碍筛查及3年随访研究  

Early screening on autism spectrum disorders in 18～24 months old children in Shenzhen:3 years follow up study.

作　　者：韦臻[1] 任路忠[2] 翁丽芬[3] 高武红[4] 何慧静[1] 王为实[2] 万国斌[1] 

机构地区：[1]南方医科大学深圳市妇幼保健院,广东深圳518048 [2]深圳市龙岗区妇幼保健院,广东深圳518052 [3]深圳市宝安区妇幼保健院,广东深圳518133 [4]深圳市南山区妇幼保健院,广东深圳518172

出　　处：《中国儿童保健杂志》2012年第4期354-357,共4页Chinese Journal of Child Health Care

基　　金：深圳市妇幼经费支持项目(2008);深圳市龙岗区科技基金项目(2010)

摘　　要：【目的】通过对18～24月龄婴幼儿进行早期孤独症谱系障碍(autism spectrum disorders,ASD)筛查并随访3年,了解深圳市ASD的患病率及早期诊断的可行性。【方法】用婴幼儿孤独症检测表(Checklist for autism intodalers,CHAT)量表对深圳市南山区、宝安区和龙岗区的3 624名婴幼儿进行筛查,对筛查阳性者进行转诊、电话访谈、诊断评估及3年随访。【结果】筛查阳性婴幼儿244人,总筛查阳性率为5.77%;共诊断ASD儿童10名,其中3例PDD-NOS,7例孤独症,总患病率为2.76‰,均为男性。第一次诊断评估为可疑ASD患儿在3年随访后仍旧符合ASD的诊断标准。【结论】深圳市ASD患病率低于国外报道结果,高于国内其他地区的报道。利用儿童保健系统进行孤独症的早期筛查具有可行性,有利于孤独症的早期诊断和早期干预。【Objective】 To investigate the prevalence and the feasibility of early diagnosis about autism spectrum disorders（ASD） in Shenzhen city by early screening on infants aged 18-24 months. 【Methods】 3 624 infants were screened by checklist for Autism in Todalers（CHAT） scale in Nanshan,Baoan,Longgang district in Shenzhen city,then screening positive infants were measured by transfer treatment,telephone interview,diagnostic evaluation and followed up for 3 years. 【Results】 244 infants were screened as positive subjects among the whole 3 624 infants and the total screening positive rate was 5.77%.There were 10 infants diagnosed as ASD,including 3 PDD-NOS,7 autisms.These infants who were suspected as ASD at the first diagnostic evaluation were still meet the same diagnosis after 3-years followed-up. 【Conclusions】 The ASD prevalence rate in ShenZhen city is lower than that reported on abroad,while is much higher than that in other regions in China.Healthy education should be strengthened to improve the social awareness of the disease and carry out early screening,early diagnosis and early intervention by the child healthcare system,which help to reduce the burden of the families and society.

关 键 词：孤独症谱系障碍 早期筛查 随访研究 

分 类 号：R749.94[医药卫生—神经病学与精神病学]